Discover the remarkable convergence of the Stem Cell and Regenerative Medicine Asia 2023 Conference with the highly regarded Biologics World Taiwan Conference. This dynamic co-location brings together influential professionals, researchers, and experts from the biopharmaceutical and regenerative medicine sectors. Experience a collaborative environment where groundbreaking ideas, cutting-edge research, and transformative solutions merge to shape the future of healthcare. Join us at this exceptional event to engage in insightful discussions, build valuable connections, and propel advancements in biologics, stem cells, and regenerative medicine.
Unlock the potential of this extraordinary gathering as the Stem Cell and Regenerative Medicine Asia Conference and Biologics World Taiwan Conference combine forces. Gain exclusive access to a diverse range of perspectives, explore innovative approaches, and seize the opportunity to contribute to the advancement of these rapidly evolving fields. Be part of this synergistic platform where knowledge meets opportunity, and together, we'll pave the way for revolutionary breakthroughs and impactful collaborations.
Stay tuned for an exciting announcement regarding the possibility of a site tour at Stem Cell and Regenerative Medicine Asia 2023 Conference.Check back soon for updates on this unique opportunity to explore cutting-edge facilities and gain firsthand insights into the world of vaccines.
Steve CL Lin
Dr. Edmund Ang, a Senior Technical Expert and joined Merck’s BioReliance Biosafety Testing in 2017. Dr. Ang provides technical support on CMC testing of biotherapeutics to biopharma developers and manufacturers in Asia Pacific. He has more than 20 years of experience in life science industry with R&D experience in cancer drug and biomarker discovery at Eli Lily and Ionis Pharmaceuticals, as well as commercial technical experience in cellular analysis and bioproduction with Roche Diagnostics, Life Technologies/Thermo Fisher Scientific.Dr. Ang obtained his Ph.D. in Cell Biology from the University of Edinburgh and conducted his postdoctoral research on cell signalling at Stanford University and National Cancer Centre, Singapore.
Frank C-J Chang
Dr. Kuan co-founded ARCE Therapeutics in 2020 and is the President and CEO. He leads ARCE from discovery toward clinical trials in developing next generation cell therapies such as CAR-engineered cells, for cancer treatment, including liquid and solid tumors, and immunological disorder diseases. He has more than 30 years of experience in research and development of therapeutic antibodies, protein fusions, and cellular gene therapy for the treatment of cancer, autoimmune, neurodegenerative and infectious diseases, including Duke University Medical Center and Development Center for Biotechnology. His areas of expertise include antibody engineering, recombinant immunotoxins, bispecific antibodies, and CAR-T/NK cell therapies for cancer treatment. Dr. Kuan obtained his Ph.D. degree from Purdue University in the USA; and his B.S. degree from National Taiwan University in Taiwan.
Bulsara, Sonia S
Hee Woo Park
Yun-Chi Lu, PhD.
Kuo-Wei Hsueh, PH.D.
Kok Li Kwang
Peggy Tseng, Ph.D
Allen Lien, MD, PhD
Jason Huang M.D ; J.D.
Hsing-Mao Chu, Ph.D.
Yi-Chun Maria Chen, PhD
D. J. Hsieh, PhD.
Kevin Chih-Yuan Ho
Cheng-Yi Jerry Kuo
Karen Wen, Ph.D.
Jan Mou Lee
William Hung, Ph.D.
The global stem cell therapy market is expected to grow at a CAGR of 16.5 percent to USD 401 million by 2026, up from USD 187 million in 2021. Due to the growing production of stem cell-based therapies, government initiatives for developing regenerative medicines, the establishment of many stem cell banks, and increasing clinical trials for regenerative medicines in the region, Asia Pacific is expected to grow at the fastest CAGR of 9.0 percent during the forecast year. For example, MEDIPOST, Korea announced the results of NEUROSTEM's phase 1/2a study in July 2020. It's an experimental stem cell therapy for the treatment of Alzheimer's disease.
To combat the pandemic, researchers have been developing new therapies and treatments. Stem cells have been shown to be an effective treatment for pulmonary disorders, like COVID-19, in recent years.
In addition, the increasing number of product development initiatives in this field, combined with the presence of several marketed products, has resulted in a significant increase in overall cell therapy manufacturing demand. As a result, cell therapy developers have turned to contract manufacturing organizations (CMOs) to meet their growth and production needs.
These opportunities include contract research and manufacturing outsourcing and rising patient population with neurological and other chronic conditions in the region. China, Japan, Singapore, and South Korea are the frontrunners and are set to dominate the APAC stem cell market in the coming year.
Adult stem cell leads the market due to low contamination during sub-culture and expansion, relatively small labor production and compatibility with the human body. Just the Induced pluripotent stem cells (IPSc’s) was expected to report revenue of over USD 4.5 billion by 2020, on account of the similar nature of its origin. With the continued growth of medical tourism hubs like India, Singapore, and Thailand, Asia is expected to maintain its place as the epicenter of stem cell research and therapy. These opportunities include contract research outsourcing and rising patient population with neurological and other chronic conditions in the region. Japan, Singapore, and South Korea are the frontrunners and are set to dominate the APAC stem cell market in the coming years.
Case Studies on Stem Cells & Regenerative Medicines from Taiwan
Gain insights on the latest case studies of stem cell and regenerative medicine and recognize the potential of the cell and gene therapies.
Advances in CAR-T Cell Therapy Development
Explore the latest CAR-T cell therapy advancements with impressive and effective solutions for antitumor treatments, especially against hematological malignancies from Taiwan's key leaders in the CAR-T cell therapy industry.
Cell & Gene Therapy Manufacturing Best Practices
Immerse in the best practices of cell & gene therapy products from the innovative showcase of the Taiwan market while considering the key factors and strategy that can lead to successful scale up and manufacturing of the products.
Cell & Gene Therapy Commercialization Strategies
Listen to the key industry leaders of cell & gene therapy about their success stories of making the commercialization of the products a successful ones while replicating the strategies of effective manufacturing and commercialization in the market.
Innovative Treatments in Cell & Gene Therapy from Taiwan
While Asia region countries like China, Korea and Japan are advancing the cell & gene therapy sector, Taiwan has also come up with innovative treatment alternatives that help to save people's lives. Dive deep into the latest innovation of cell & gene therapy from the Taiwan stories and get amazed!
Sartorius Stedim Biotech is a leading partner of the biopharma industry. Our solutions support our customers in producing drugs safely, timely and economically. The key product categories of our company are cell cultivation, fermentation, filtration, purification, and fluid management.
Merck, a leading science and technology company, operates across life science, healthcare and
electronics. To the life science industry, we provide solutions and services for research,
biotechnology development and production, and pharmaceutical drug therapy development
The Millipore® portfolio of Merck offers an ecosystem of industry-leading products and
services, spanning preparation, separation, filtration, and monitoring, as well as clinical and
commercial biomanufacturing CTDMO services - all of which are deeply rooted in quality,
reliability and time-tested processes. The SAFC® portfolio of Merck offers customized and
ready-to-use raw material solutions, backed by deep regulatory expertise. Our proven products,
expert services and regulatory and application expertise are a strong foundation you can rely on
to consistently perform at the highest level.
For more information, please visit https://www.merckmillipore.com and
Cytiva is a global life sciences leader with more than 8,000 associates across 40 countries dedicated to advancing and accelerating therapeutics. As a trusted partner to customers that range in scale and scope, Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the development, manufacture, and delivery of transformative medicines to patients.
Halo Labs knows aggregates and particles. The Aura can count and characterize subvisible particles and tell you if they are aggregated drug product, excipients, or external contaminants. A simple, plate-based approach enables low-volume, high-throughput, fully automated particle imaging and analysis at any stage from developability assessment through quality control.”
Pall Corporation provides critical filtration, separation, and purification solutions to meet the demanding needs of a broad spectrum of life sciences and industrial customers around the globe. Across 80 locations and 10,000 people worldwide, we are unified by a singular drive: to solve our customers' biggest fluid management challenges. And in doing so advance health, safety, and environmentally responsible technologies. Together, our Life Sciences and Industrial teams serve a diverse range of customers including biotechnology, pharmaceutical, medical, food and beverage, laboratory, microelectronics, aerospace, fuels, petrochemical, chemical, automotive and power generation industries. Our industry-leading technologies and solutions are at work in countless applications, protecting critical operating assets, improving product quality, safeguarding the health, and minimizing emissions and waste
For more info, please check: https://www.pall.com/en/biotech.html
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.
For more information, please visit www.thermofisher.com
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of lifesaving and life-enhancing medicines for patients. With almost 10,000 team members across 50 sites worldwide, West helps support our customers by delivering over 40 billion components and devices each year.
Headquartered in Exton, Pennsylvania, and in business for nearly a century, West in its fiscal year 2020 generated over $2.147 billion in annual revenue. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor's 500 index. For more information, visit www.westpharma.com.
Elsevier, a global leader in information and analytics, helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We extract reliable data from scientific literatures to support corporate R&D professionals save time, make better decisions and innovate. Our life science solutions for pharmaceutical customers including, Reaxys, ScienceDirect, Scopus, Embase and Pharmapendium, which combine trusted data and analytics to help you answer critical drug discovery and business questions, including efficiently monitoring post-market drug safety literatures.
CPC (Colder Products Company) is the leader in single-use connection technology, offering a wide variety of connectors for biopharmaceutical manufacturing. Innovative, flexible designs easily combine multiple components and systems including process containers, tubing manifolds, transfer lines, bioreactors and other bioprocess equipment. Robust single-use connectors maintain media sterility and integrity while improving production yields, decreasing time to market and reducing costs. The company’s well-known AseptiQuik® and MicroCNX connectors provide quick and easy sterile connections even in non-sterile environments. Learn more about these connectors and our entire portfolio at cpcworldwide.com/bio. Connect with confidence with CPC, an operating company within Dover Corporation.
GenScript is a global biotechnology group. GenScript’s businesses encompass four major categories based on its leading gene synthesis technology, including operation as a Life Science CRO, enzyme and synthetic biology products, biologics development and manufacturing, as well as cell therapy.
Founded in 2002 and listed on the Hong Kong Stock Exchange in 2015, GenScript has an established global presence across Greater China, North America, the EU, and Asia Pacific. Today, over 300,000 customers from over 160 countries and regions around the world have used GenScript’s premier, convenient, and reliable products and services.
GenScript currently has more than 3000 employees globally, 33% of whom hold master’s and/or Ph.D. degrees. In addition, GenScript has a number of leading commercial technologies developed in the fields of synthetic biology, immunotherapy, antibody design, chemical synthesis and bioinformatics, including more than 70 patents and over 200 patent applications. As of January 2019, GenScript's products and services have been cited by 36,500 scientific papers worldwide.
GenScript is committed to striving towards its vision of being the most reliable biotech company in the world to make humans and nature healthier through biotechnology.
For more information, visit www.genscript.com
Principal Contact Name: Cassie Yap/ Boon Hwa Tay
Email Address: [email protected] / [email protected]
Position: Marketing Supervisor / Marketing Specialist
Marken is a wholly owned subsidiary of UPS and is a critical part of UPS Healthcare. With Polar Speed and Marken included, the UPS Healthcare division staffs 128 locations with 5,500 employees worldwide. Marken offers a state-of-the-art GMP-compliant depot network and logistic hubs for clinical drug product storage and distribution in 59 locations worldwide, while maintaining the leading position for Direct-to-Patient and Home Healthcare services, biological sample shipments and biological kit production.
Marken’s dedicated 2,000 staff members manage 135,000 drug product and biological sample shipments every month at all temperature ranges in more than 220 countries and territories and have orchestrated 11,500+ home healthcare visits. Additional services such as cell and gene supply chain services, ancillary material sourcing, storage and distribution, shipment lane verification and qualifications, as well as GDP, regulatory and compliance consultancy add to Marken’s unique position in the pharma and logistics industry.
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
Novo Nordisk Pharmatech A/S is a global and leading manufacturer of pharmaceutical ingredients for the pharmaceutical and biopharmaceutical industries. The company specialises in Recombinant Insulin and cGMP manufactured quaternary ammonium compounds (Quats).
The mission is to enable better medicines by providing sustainable pharmaceutical materials through innovative and customised solutions. Novo Nordisk Pharmatech helps the world´s largest pharmaceutical and biopharmaceutical industries reducing their risk for raw materials by using pharma-grade products with a high level of consistency, purity, quality, and reliability.
Novo Nordisk Pharmatech´ s high purity, non-therapeutic Insulin is sourced directly from parent company Novo Nordisk, the world’s largest insulin producer. Recombinant Insulin stimulates the proliferation of cells, enhances the yield, and is a key component in serum-free growth media for mammalian cells. It is used to manufacture monoclonal antibodies, virus vaccines, gene therapy products and other biological drug products approved by regulatory bodies worldwide, including FDA and EMA.
Novo Nordisk Pharmatech manufactures Quats in an unequalled, full cGMP grade, ensuring exceptionally high purity and batch-to-batch consistency. Benzalkonium Chloride, Cetrimide and Cetrimonium Bromide/CTAB) is suited for a wide range of pharmaceutical applications that require high purity and quality, such as vaccine production. And as preservatives (excipients) or APIs in many ophthalmic, nasal, oral and topical drugs and in various solutions, ointments, gels, and creams.
More than 70 years of experience has provided the know-how to ensure maximum product purity and keeping impurities to even lower levels than pharmacopeial standards. This has made the company a leading global supplier of high-quality ingredients - enabling the customers to make even better medicines.
Novotech Is Internationally Recognized as The Leading Asia Pacific Contract Research Organization with Global Execution Capabilities (CRO).
Novotech is the leading Asia-Pacific biotech specialist CRO with global execution capabilities. Novotech is a clinical CRO with labs, phase I facilities, and drug development consulting services. It has accumulated experience in over 3,700 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. Novotech is positioned to serve biopharmaceutical clients conducting clinical trials in Asia, the US and globally. With the acquisition of a US based CRO in May 2022, Novotech has over 2500 FTEsand contracting monitors working across our offices in 11 geographies in Asia-Pacific and the United States.
Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety solutions, central lab services, report write-up to ICH requirements, project and vendor management. Novotech obtained the ISO 27001 certification which is the best-known standard in the ISO family providing requirements for an Information Security Management System. Together with the ISO 9001 Quality Management system, Novotech aims at the highest IT security and quality standards for patients and biotechnology companies.
Taiwan Research-based Biopharmaceutical Manufacturers Association (TRPMA)
TRPMA on behalf of Taiwanese R&D-based biopharmaceutical and regenerative medicine industry is actively promoting life science R&D, capital investment, business alliances and international collaborations. Our mission is to build up a globally competitive value chain of the innovative life science industry to boost Taiwan’s economy and to enhance the health and welfare of global people.
EARLY BIRD: End User
- 2-Day Conference Access
- Expires 29th September 2023
- Add on Sites Tour/ Poster Presentation at SGD400
- Full price SGD 3195
EARLY BIRD: Vendor/BD
- 2-Day Conference Access
- Expires 29th September 2023
- Add on Sites Tour at SGD400
- Full price SGD 4895
Present your expertise to the key cell and gene therapy stakeholders from Asia through a variety of available speaking packages.
Join the exhibition, and build an impressive presence among your potential clients.
Emphasize on your messages by promoting your brand alongside exhibition and thought leadership.
Engage with and build lasting connections that matter the most to your business.
Gain exclusive access to contacts of high-profile attendees through intimate networking opportunities.